Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Biotechnology

Healthcare
$149.40 -2.22%

-$6.27 today

Market cap
$20.01B
Beta
0.27
P/E (TTM)
63.6
EPS (TTM)
$4.34
52W Low $273.11High $495.55

Volume 2.52M

Average 1.11M

ALNY EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA growth accelerates

Q2 FY2026 EBITDA of $245.07M rose 1201.3% year over year, ahead of the +773.6% change in trailing-twelve-month EBITDA. Sequentially, it fell 19.5% from the prior quarter.

Context

  • EBITDA amounted to 17.0% of revenue in FY2025, up 9.0 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 21 analysts of $3.46B (+448.6%) for the fiscal year ending Dec 2026, a slowdown from the +453.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$245.07M-19.5% QoQ
Last fiscal yearDec 2025
$631.44M+453.1% YoY
LTMJun 2026
$1.15B+773.6% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1201.3%+15.1%-1186.2 pp
1 year+453.1%+448.6%-4.5 pp
3-year CAGR—+53.7%—
5-year CAGR+31.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
631.44M USD
Year-over-year change
+453.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ALNY compares with its peers on the latest reported figures

  • ALNY's LTM Jun 2026 EBITDA of $1.15B is the highest of the 6 companies compared; the peer median is -$384.61M.
  • Its year-over-year change of +773.6% is the highest of 5, against a peer median of -138.3%.
  • EBITDA amounts to 24.0% of revenue for ALNY, versus a peer median of 243.2%.
ALNY Competitors Peer median
EBITDA for ALNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.15B +773.6%—24.0%
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M ——8478.5%
WVEWave Life Sciences Ltd.LTM Mar 2026-$174.59M -68.4%—243.2%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$384.61M +25.4%—581.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$473.54M -208.3%—49.3%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$603.58M -466.2%—133.9%
Peer median (excluding ALNY) -$384.61M-138.3%—243.2%

Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue844.29M1.04B1.83B2.25B3.71B
Cost of Revenue140.14M168.82M310.41M323.37M677.17M
Gross Profit704.14M868.6M1.52B1.92B3.04B
Gross Margin83.4%83.7%83.0%85.6%81.8%
Research & Development792.16M883.02M1B1.13B1.32B
Selling, General & Admin620.64M770.66M795.65M975.53M1.21B
Operating Expenses1.41B1.65B1.8B2.1B2.54B
Depreciation & Amortization47.57M44.47M54.05M56.67M55.66M
EBITDA(661.56M)(926.56M)(258.24M)(178.85M)631.44M
EBITDA Margin-78.4%-89.3%-14.1%-8.0%17.0%
Operating Income(708.65M)(785.07M)(282.18M)(176.89M)501.58M
Operating Margin-83.9%-75.7%-15.4%-7.9%13.5%
Interest Income1.58M24.81M95.56M121.99M111.47M
Interest Expense143.02M155.97M121.22M141.86M252.63M
Other Income / Expenses(143.49M)(341.92M)(151.34M)(200.49M)(178.43M)
Income Before Tax(852.14M)(1.13B)(433.52M)(377.38M)323.15M
Pre-Tax Margin-100.9%-108.6%-23.7%-16.8%8.7%
Income Tax Expense680K4.16M6.73M(99.22M)9.41M
Net Income(852.82M)(1.13B)(440.24M)(278.16M)313.75M
Net Margin-101.0%-109.0%-24.1%-12.4%8.4%
EPS (Basic)(7.20)(9.30)(3.52)(2.18)2.39
EPS (Diluted)(7.20)(9.30)(3.52)(2.18)2.33
Weighted Avg Shares118.45M121.69M124.91M127.65M131M
Weighted Avg Shares (Diluted)118.45M121.69M124.91M127.65M134.68M

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Intrinsic Alpha fair value

Locked

Current Price

$149.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.